Clinical trial
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)
NCT00111709 · Organon and Co, Industry · Completed
Key facts
| NCT number | NCT00111709 |
|---|---|
| Title | Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071) |
| Official title | A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine |
| Lead sponsor | Organon and Co, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | MK0462, rizatriptan benzoate / Duration of Treatment -1 day, Comparator: placebo / Duration of Treatment - 1 day |
| Enrollment | 393 |
| Start date | May 27, 2005 |
| Primary completion | Feb 24, 2006 |
| Completion | Feb 26, 2006 |
| First posted | May 25, 2005 |
| Last update posted | Aug 14, 2024 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: